Table 5 Anticancer activity of biological metal nanoparticles
Biological agent used for synthesis | Nanoparticle | Cell line | IC50 value | Reference |
|---|---|---|---|---|
Marsilea quadrifolia | Silver | Human ovarian teratocarcinoma (PA-1) and lung adenocarcinoma (A549) | 45.88 μg/mL and 52.015 μg/mL | [25] |
Morinda pubescens | Silver | HEP G2 (Human Epithelium cells of liver cancer | 937 μg/mL | [129] |
Nepeta deflersiana | Silver | Human cervical cancer cells (HeLa) | 5 μg/mL | [130] |
Murraya koenigii | Silver | HT-29 colon cancer | 26.05 μg/mL | [131] |
Cyanobacterium Nostoc sp. strain HKAR-2. | Silver | MCF-7 cells | 27.5 μg/mL. | [132] |
Piper nigrum | Silver | MCF-7 and Hep-2 cells | 52 mL, 54 μg/mL | [133] |
Ficus religiosa | Silver | A549 and Hep2 cells | 1.9 μg/mL and 1.6 μg/mL | [134] |
Solanum xanthocarpum | Gold | HCT 15 human colon cancer | – | [135] |
Streptomyces sp. | Gold | HeLa | 350 μg/mL | [136] |
Evolvulus alsinoides | Palladium | Human ovarian cancer A2780 cells | – | [137] |
Gloriosa superb | Platinum and palladium | MCF-7 (human breast adenocarcinoma | 49.65 ± 1.99% and 36.26 ± 0.91% | [138] |
Barleria prionitis | Platinum Paladium | Human breast adenocarcinoma (MCF-7) | – | [139] |
Sargassum muticum | Iron oxide nanoparticles | HeLa cells, MCF-7 cells, HepG2 cells, and human cell lines for leukemia Jurkat | 1.1 μg/mL (HepG2), 18.75 ± 2.1 μg/mL (MCF-7), 12.5 ± 1.7 μg/mL (HeLa), and 6.4 ± 2.3 μg/mL (Jurkat) | [140] |
Albizia lebbeck | Zinc oxide | MDA-MB 231 and MCF-7 | 48.5, 48.7, and 60.2 μg/mL | [107] |
Costus pictus D. Don medicinal | Zinc oxide | DLA | – | [63] |
black bean extract | Copper oxide | HeLa | – | [115] |
Ficus religiosa | Copper oxide | A549 cells | 200 μg/mL | [127] |